Introduction
Pregnant women, especially primigravidas, are more vulnerable than non-pregnant women to malaria infections. Infection may result in stillbirth, low birthweight infants, and anaemia in the mother. '4 The World Health Organisation recommends that pregnant women receive chemoprophylaxis with chloroquine base, 5 mg/kg body weight weekly, in areas where Plasmodium falciparum is sensitive to the drug. ' In 1986 it was reported that chloroquine 5 mg/kg weekly and chloroquine 25 mg/kg monthly did not completely protect pregnant women in western Kenya. 6 We found in 1987 that 90% of infections with P falciparum in children under 5 years in western Kenya were resistant to chloroquine (unpublished data).
Two alternatives to chloroquine, amodiaquine and pyrimethamine with sulfadoxine, are no longer recommended for routine prophylaxis because of serious, though uncommon, side effects.79 The dihydrofolate reductase inhibitors pyrimethamine and chlorproguanil are not effective as prophylactic drugs in Kenya when given alone.'0-'2 Therefore only a limited number of drugs is available for effective prophylaxis.
A recent report indicates that the combination of chlorproguanil and dapsone is more effective than pyrimethamine and sulfadoxine in vitro and as effective in vivo against P falciparum in Kenya. '3 Because the chlorproguanil and dapsone combination is eliminated more rapidly than pyrimethamine and sulfadoxine, in one week compared with about eight weeks, chlorproguanil and dapsone may exert less pressure than pyrimethamine and sulfadoxine for the emergence of resistant parasites when the combination is given for treatment. Furthermore, the cost ofa single dose of chlorproguanil and dapsone is the same as for a course of chloroquine, and the chlorproguanil and dapsone combination is considerably less expensive than pyrimethamine and sulfadoxine. (6) 2/36 (6) 2/36 (6) 2/36(6) 5/35 (14) 5/34 ( Nulligravid women who attended a secondary boarding school were screened and assigned to the same types of treatment groups as the pregnant women. That they were not pregnant was confirmed by a urine test for human chorionic gonadotropin. At day 14 after treatment urine was collected from those who had received pyrimethamine and sulfadoxine to measure pyrimethamine and sulfadoxine levels by ELISA.
Comparisons were done with Student's t test, the x2 test, and Fisher's exact test.
Results

STUDY POPULATION
Of 988 pregnant women who were screened, 182 (18%) fulfilled the study criteria and 158 were included in the final analysis. Primigravidas were parasitaemic (>500 parasites/pl) more often than multigravidas, 41% (101/249) and 11% (81/739) respectively. Of 1488 non-pregnant women, 105 (7%) were enrolled as controls: the mean age of the nonpregnant women in the three treatment groups was the same, and there were no differences in age, period of gestation, or parity among the three treatment groups of pregnant women. Table I shows the characteristics of the study population by number of pregnancies. Mean age increased with an increase in the number of pregnancies, as would be expected. The initial geometric mean density of parasite was significantly higher in the primigravid women than in the other groups (p<005).
RESPONSE TO TREATMENT Table II shows response to the various treatment regimens. At day 7 chlorproguanil with dapsone and pyrimethamine with sulfadoxine were significantly better than chloroquine at clearing parasites in nulligravidas and primigravidas (p<0 05); at that point there was no difference between the regimens in multigravidas. The proportion of women who remained free of parasites at day 14 and day 21 was higher among those who received either chlorproguanil and dapsone or pyrimethamine and sulfadoxine, regardless of gravid state, than in those given chloroquine (p<005). By day 21 the proportion of primigravid recipients of chlorproguanil and dapsone who were again infected had begun to increase, and it was similar to that in BMJ VOLUME 301chloroquine recipients by day 35. A slower but similar increase was seen in multigravid recipients of chlorproguanil and dapsone. Among all pregnant women significantly fewer recipients of pyrimethamine and sulfadoxine had become infected by day 42 (p<0-01).
The initial geometric mean parasite density in the primigravid women who became positive at day 14 after treatment with chlorproguanil and dapsone was significantly higher than that in women who were aparasitaemic on that day (7293 and 1633 respectively, p<005). In the other groups of women the initial density of parasites was not related to subsequent reappearance of infection.
Less than 16% of subjects in all groups reported using chloroquine in the preceding two weeks. Use of chloroquine was not related to subsequent development of parasitaemia in any treatment group.
In urine samples collected from recipients of chlorproguanil and dapsone on day 1 chloroquine could be detected in only one sample, but chlorproguanil and dapsone could be detected in all samples. A few urine samples were positive for chlorproguanil and dapsone at day 7. In urine samples collected from nulligravid recipients of pyrimethamine and sulfadoxine at day 14 pyrimethamine and sulfadoxine were present in all except one sample. The woman whose urine lacked these drugs was parasitaemic on day 14 . of primigravidas, and 15% of nulligravidas were parasitaemic by day 14 after treatment with chloroquine 25 mg/kg (table II) .
HAEMOGLOBIN CONCENTRATIONS
Pyrimethamine with sulfadoxine and chlorproguanil with dapsone were equally effective for treatment of falciparum malaria and superior to chloroquine in all women. In addition, the parasite density in pregnant women with infection on days 7 and 14 was significantly lower for those receiving pyrimethamine with sulfadoxine and chlorproguanil with dapsone than for those receiving chloroquine. Chloroquine use in the preceding two weeks was not related to the response to any treatment. Pyrimethamine with sulfadoxine kept patients free of parasites longer than the other drugs did, most likely because of its longer half life. Of the primigravid women, 81% remained aparasitaemic through to day 28 after receiving pyrimethamine with sulfadoxine compared with 33% who received chlorproguanil with dapsone and 24% who received chloroquine. We do not know if the placentas were infected; no good correlation has been found between the parasite density in peripheral blood and in the placenta of women with well developed immunity. 34 We found a rise in haemoglobin concentration from day 0 to day 28 for all pregnant women except primigravid recipients of chloroquine. A relation between absence of peripheral parasites from day 0 to day 28 and an increase in haemoglobin was not found but might have been found ifwe had not treated the women who were positive for parasites and who had symptoms of malaria before day 28 23 Hypersensitivity reactions were thought to occur after several weeks of more than 100 mg dapsone daily,'9 24 but recently the so called dapsone syndrome was noticed after only four weeks of Maloprim (dapsone 100 mg and pyrimethamine 12 5 mg) and chloroquine 300 mg taken weekly for prophylaxis. 25 Except for chlorproguanil all the drugs we used have been studied in pregnancy. No embryotoxic or teratogenic effects were noted in pregnant rats fed high doses of proguanil or cycloguanil,26 but inhibition of development of ova during cleavage was found.27 Proguanil and chlorproguanil have been widely recommended for prophylaxis in pregnancy and have been used without apparent adverse effects. Pyrimethamine has been reported to be teratogenic when given in high doses to rats, although teratogenicity has never been observed in humans. Maloprim has no embryopathic effect when given in a single dose each week. [28] [29] [30] Sulpha drugs compete with bilirubin and could cause raised concentrations of unbound bilirubin, and possibly kernicterus, in neonates. However, this is seldom seen after sulphonamide use."' A teratogenic effect of sulfadoxine has been looked for in animals32 and pregnant women29"3 but has not been observed. SDDS (2-sulphamoyl-4,4-diamino-diphenylsulphone) was not teratogenic when given to rats.27 A low incidence (3-4%) of defects was seen in children born to women with leprosy who took sulphones during pregnancy.34
The World Health Organisation advocates pyrimethamine with sulfadoxine for the treatment in pregnancy of falciparum malaria resistant to chloroquine.5 Resistance to pyrimethamine and sulfadoxine is still uncommon in Kenya," but extensive use of this drug combination has led to the emergence of parasites resistant to the drug in South East Asia.36 Because the development of a higher level of resistance to pyrimethamine and sulfadoxine remains a risk in Africa we believe that it is desirable to study other drug combinations.
The combination of chlorproguanil and dapsone has not been investigated in pregnant animals or women, as far as we know. In Vietnam dapsone 25 mg was added to proguanil 200 mg by the Australian military because prophylaxis with proguanil failed. The frequency of malaria attacks dropped dramatically after this measure. 23 The low doses of chlorproguanil and dapsone, which have no documented teratogenicity when given on their own, and the lack of side effects observed by us and others'3 lead us to believe that chlorproguanil and dapsone is probably a safe drug combination. Experimental testing would, however, be required to confirm that the combination is safe before its use could be widely recommended. The advantages of chlorproguanil and dapsone over pyrimethamine and sulfadoxine are those of stronger activity against Kenyan P falciparum in vitro'3 and lower cost. It is possible that no drug will maintain the placenta entirely free of parasites, but this may not be necessary to prevent anaemia in the mother and low birth weight of the baby.
Giving a drug during monthly antenatal clinic visits would assure better compliance, and the drug might have a beneficial effect on maternal anaemia and pregnancy outcome if it reliably cured peripheral parasitaemia. Chlorproguanil and dapsone as a drug combination for such intervention in pregnancy warrants further study. Traditionally, doctors obtain continuing medical education from postgraduate meetings and medical journals. Other potential sources are professional correspondence, the lay press, pharmaceutical representatives, informal meetings with professional colleagues, and patients. Letters are important in "the educative role of consultants"2 and as a medium for "the process of mutual education."5 It could therefore be asked whether and to what extent general practitioners receive education in replies from orthopaedic surgeons in response to their referral letters; whether those general practitioners in most need of such education (as indicated by poor content of the referral letter) receive it most often; and whether general practitioners impart any education regarding the patients they refer.
Studies have analysed the contents (but not the educational potential) of letters for general medical and psychiatric referrals,' 56 but no studies have examined orthopaedic referrals and their replies. Thus the aims of this study were to assess: the delay between writing the referral letter and the outpatient appointment; the content ofthe referral letters from general practitioners to orthopaedic surgeons and their associated replies; the extent to which mutual education occurs between general practitioners and orthopaedic surgeons and the factors that influence such education; and the extent to which questions asked by referral letters are answered in the reply.
Method
Referrals to elective outpatient clinics of 16 October 1988 were used. The referral letter(s) and all replies from orthopaedic surgeons to the general practitioner in the month after the patient was seen were photocopied. Any details identifying authors were coded and then removed before assessment.
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